A multicenter, double-blind, placebo and active controlled, randomized study to evaluate the safety and efficacy of the addition of sitagliptin 100 mg once daily in patients with type 2 diabetes with inadequate glycemic control on metformin monotherapy

Trial Profile

A multicenter, double-blind, placebo and active controlled, randomized study to evaluate the safety and efficacy of the addition of sitagliptin 100 mg once daily in patients with type 2 diabetes with inadequate glycemic control on metformin monotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Sitagliptin (Primary) ; Metformin; Rosiglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 29 Jan 2009 Rosiglitazone and metformin identified as an additional treatment arms as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Actual patient numbers (273) added as reported by ClinicalTrials.gov.
    • 29 Jan 2009 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top